Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q3 FY24 results · Oct–Dec 2023
Panacea Biotec reported revenue from operations of ₹150.50 crore (up 30.6% from Q3 FY23) and net loss of ₹2.20 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 150.50 | 115.20 | +30.6% | 143.02 | +5.2% |
| Other income | 5.68 | 13.94 | −59.3% | 3.23 | +75.9% |
| Total income | 156.18 | 129.14 | +20.9% | 146.25 | +6.8% |
| Profit before tax | (1.65) | 22.44 | Turned loss | (7.78) | Loss narrowed |
| Net profit for the period | (2.20) | 19.37 | Turned loss | (8.29) | Loss narrowed |
| EPS, basic (₹) | (0.37) | 3.16 | Turned loss | (1.35) | Loss narrowed |
| Net margin (%) | -1.5 | 16.8 | -5.8 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 95.23 | 71.97 | +32.3% | 94.59 | +0.7% |
| Other income | 3.05 | 9.71 | −68.6% | 2.13 | +43.2% |
| Total income | 98.28 | 81.68 | +20.3% | 96.72 | +1.6% |
| Profit before tax | 1.07 | 13.24 | −91.9% | 3.20 | −66.6% |
| Net profit for the period | 0.43 | 13.24 | −96.8% | 3.20 | −86.6% |
| EPS, basic (₹) | 0.07 | 2.16 | −96.8% | 0.52 | −86.5% |
| Net margin (%) | 0.5 | 18.4 | 3.4 |
Consolidated
- Filed with BSE
- 24 Feb 2024, 13:50 IST
- Board meeting
- 13 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Feb 2024, 13:50 IST
- Board meeting
- 13 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE